anistreplase

(redirected from Eminase)

anistreplase

 [an″is-trep´lās]
a thrombolytic agent primarily used to clear coronary vessel occlusions associated with myocardial infarction; administered intravenously.

anistreplase

See APSAC.

anistreplase

A clot-dissolving drug used to try to re-establish blood flow in the heart muscle in the early treatment of heart attacks. A brand name is Eminase.
References in periodicals archive ?
The three agents in this category are anistreplase (Eminase) and streptokinase (Streptase), both rated C, and urokinase (Abbokinase).
The pricing decision also has left the product open to vicious competition from $1,700-a-dose Eminase, produced by SmithKline Beecham, and Astra Kabi's streptokinase, priced at $200 a dose.
That's an interesting choice of figures, given that your Activase, priced at $2,200 per dose, is facing some competition from $1,700-a-dose Eminase, produced by Smithkline Beechman, and streptokinase, a $200-a-dose product put out by Astra Kabi.
makes streptokinase, which has been linked to fewer strokes than either Genentech Inc.'s tPA or SmithKline Beecham PLC's Eminase. Per-dose cost for those drugs are $2,200 and $1,700, respectively, compared with a cost ranging from $76 to $300 per dose for streptokinase.
Researchers at Oxford University report that the frequency of strokes in a group they studied was three for every 1,000 patients who were treated with streptokinase, compared with six in 1,000 who took Eminase and seven of 1,000 who used tPA.
"We see sales of Tagamet, its topselling antiulcer drug, holding steady at $1 billion, while newer drugs (most notably Augmentin, Eminase, Paroxetin and Relifex) should bolster drug sales and margins."
"We believe that the FDA is close to approving Eminase, a new clot-dissolving drug," he states.